These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 29893424)

  • 1. LncRNA TNRC6C-AS1 regulates UNC5B in thyroid cancer to influence cell proliferation, migration, and invasion as a competing endogenous RNA of miR-129-5p.
    Hou S; Lin Q; Guan F; Lin C
    J Cell Biochem; 2018 Nov; 119(10):8304-8316. PubMed ID: 29893424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing long non-coding RNAs nicotinamide nucleotide transhydrogenase antisense RNA 1 inhibited papillary thyroid cancer cell proliferation, migration and invasion and promoted apoptosis via targeting miR-199a-5p.
    Wang D; Zheng Y
    Endocr J; 2021 May; 68(5):583-597. PubMed ID: 33612561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis.
    Chen N; Yin D; Lun B; Guo X
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30429236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA PITPNA-AS1 regulates UNC5B expression in papillary thyroid cancer via sponging miR-129-5p.
    Mei S; Zong H; Zhou H
    Int J Biol Markers; 2021 Mar; 36(1):10-19. PubMed ID: 33706585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lncRNA UNC5B-AS1 promotes proliferation, migration, and invasion in papillary thyroid cancer cell lines.
    Wang Y; Bhandari A; Niu J; Yang F; Xia E; Yao Z; Jin Y; Zheng Z; Lv S; Wang O
    Hum Cell; 2019 Jul; 32(3):334-342. PubMed ID: 30805847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA MCM3AP-AS1 promotes proliferation and invasion through regulating miR-211-5p/SPARC axis in papillary thyroid cancer.
    Liang M; Jia J; Chen L; Wei B; Guan Q; Ding Z; Yu J; Pang R; He G
    Endocrine; 2019 Aug; 65(2):318-326. PubMed ID: 31030335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of LncRNA FOXD3-AS1 suppresses the aggressive biological behaviors of thyroid cancer via elevating miR-296-5p and inactivating TGF-β1/Smads signaling pathway.
    Chen Y; Gao H; Li Y
    Mol Cell Endocrinol; 2020 Jan; 500():110634. PubMed ID: 31678422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DLG1-AS1/miR-497/YAP1 axis regulates papillary thyroid cancer progression.
    Huang Y; Zhang K; Li Y; Dai Y; Zhao H
    Aging (Albany NY); 2020 Nov; 12(22):23326-23336. PubMed ID: 33197895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NR2F1-AS1 regulated miR-423-5p/SOX12 to promote proliferation and invasion of papillary thyroid carcinoma.
    Yang C; Liu Z; Chang X; Xu W; Gong J; Chai F; Cui D
    J Cell Biochem; 2020 Feb; 121(2):2009-2018. PubMed ID: 31692033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA LIFR-AS1 suppressed the proliferation, angiogenesis, migration and invasion of papillary thyroid cancer cells via the miR-31-5p/SIDT2 axis.
    Yi D; Zhang D; He J
    Cell Cycle; 2021 Dec; 20(24):2619-2637. PubMed ID: 34781815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
    Bai T; Liu Y; Li B
    IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA NEAT1 regulate papillary thyroid cancer progression by modulating miR-129-5p/KLK7 expression.
    Zhang H; Cai Y; Zheng L; Zhang Z; Lin X; Jiang N
    J Cell Physiol; 2018 Oct; 233(10):6638-6648. PubMed ID: 29319165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA CALML3-AS1 suppresses papillary thyroid cancer progression via sponging miR-20a-5p/RBM38 axis.
    Zhang X; Zhang X; Jia Q; Li H; Ma R; Yang G; Yin F; Jiang N; Yin D
    BMC Cancer; 2022 Mar; 22(1):344. PubMed ID: 35351042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H
    Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNRC6C-AS1 Promotes Thyroid Cancer Progression by Upregulating LPAR5 via miR-513c-5p.
    Tong C; Wang C; Wang Y; Xiao X
    Cancer Manag Res; 2021; 13():6141-6155. PubMed ID: 34393509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CERS6-AS1 Facilitates Oncogenesis and Restrains Ferroptosis in Papillary Thyroid Carcinoma by Serving as a ceRNA through miR-497-5p/LASP1 Axis.
    Huang T; Guan S; Wang C
    Ann Clin Lab Sci; 2022 May; 52(3):426-438. PubMed ID: 35777805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Knockdown of circPUM1 impedes cell growth, metastasis and glycolysis of papillary thyroid cancer via enhancing MAPK1 expression by serving as the sponge of miR-21-5p.
    Li Y; Qin J; He Z; Cui G; Zhang K; Wu B
    Genes Genomics; 2021 Feb; 43(2):141-150. PubMed ID: 33481227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of LncRNA UNC5B-AS1 on adhesion, invasion and migration of lung cancer cells and its mechanism].
    Tan JJ; Long SZ; Zhang T
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 Nov; 36(6):622-627. PubMed ID: 33719270
    [No Abstract]   [Full Text] [Related]  

  • 20. Long non-coding RNA ASMTL-AS1 inhibits tumor growth and glycolysis by regulating the miR-93-3p/miR-660/FOXO1 axis in papillary thyroid carcinoma.
    Feng Z; Chen R; Huang N; Luo C
    Life Sci; 2020 Mar; 244():117298. PubMed ID: 31953163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.